Dompé Looks Beyond In-Licensing
Executive Summary
Mid-sized Italian drug firm Dompé has made its name as an astute local marketer. Yet the company is now talking up its in-house R&D programs, acknowledging that a pure in-licensing model may not work forever.
You may also be interested in...
Chiesi's First Step Into Germany
Buying a foothold in Germany filled an important gap in Chiesi's European expansion strategy. But the privately owned Italian group may have to loosen up its dealmaking style to continue to clinch the deals it needs.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.